RYTM Q3'26 Earnings: EPS estimate is (0.71) USD

What happened

Rhythm Pharmaceuticals is scheduled to announce Q3'26 results on November 3 before the market opens, with disclosure expected at 7:00 a.m. ET. The article estimates revenue at 85.57 million USD and earnings per share, meaning profit or loss for each share, at negative 0.71.

Confirmed

Global impact / market context

The results will show whether reported sales and loss per share match the estimates. A revenue shortfall could signal weaker demand or sales execution, while a larger loss could mean costs are absorbing more cash; either outcome may change investors’ expectations for the company.

Analyst inference

The article lists prior quarterly revenue estimates and reported results, with reported revenue above estimates in each of the four quarters shown. It also shows varying earnings-per-share surprises, so the upcoming report may be judged against both its forecast and recent results.

Confirmed

What to watch

1. Compare reported Q3 revenue with the 85.57 million USD estimate; the gap will show whether sales were above or below the forecast stated in the article. Analyst inference
2. Compare reported earnings per share with the negative 0.71 estimate; this shows how the reported loss per share compares with the forecast, not cash available. Analyst inference
3. Look for company explanations of sales or costs alongside the results; the article provides estimates and a release time, but no reasons behind those forecasts. Analyst inference

Evidence

• Original source link unavailable